Elizabeth A Eisenhauer

Primary care providers' experiences with and perceptions of personalized genomic medicine.

Baukje Miedema, Eva Grunfeld, Mary Ann O'Brien, 2016, Canadian family physician Medecin de famille canadien.

Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

E. Eisenhauer, Elizabeth A Eisenhauer, R. El-Maraghi, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice.

E. Eisenhauer, W. Parulekar, Wendy R Parulekar, 2004, Journal of the National Cancer Institute.

Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.

Christopher Poole, Tien Le, Susan Ellard, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.

Donna Niedzwiecki, Edward L Korn, Michael B Atkins, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).

G. Giaccone, E. Eisenhauer, L. Seymour, 2008, European journal of cancer.